What's new

Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Status: Authorised

Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Status: Authorised

Mar 17, 2025 - 16:54
 0
Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Status: Authorised
Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Status: Authorised
Read More

Tags:

Previous Article

Orca Bio to seek approval of T cell transplant after positive trial data

Next Article

Quest Nutrition debuts high-protein shake

Related Posts

Human medicines European public assessment report (EPAR): Recarbrio, imipenem,cilastatin,relebactam, Date of authorisation: 13/02/2020, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 7, 2025  0

Human medicines European public assessment report (EPAR): Veoza, fezolinetant, Date of authorisation: 07/12/2023, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 14, 2025  0

Regulation (EU) 2024/568: Questions and answers clinic for the Veterinary Industry stakeholders, Online, European Medicines Agency, Amsterdam, the Netherlands, from 11 February 2025, 15:00 (CET) to 11 February 2025, 16:00 (CET)

Regulation (EU) 2024/568: Questions and answers clinic ...

Feb 13, 2025  0